MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Health Services Research
|Official Title:||MeFirst: A Tailored Intervention to HPV Vaccine Decision Making|
- Determine the effect of Me First, a tailored, online HPV vaccination decision-making guide on HPV vaccination intention and/or uptake. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Determine the effect of Me First on HPV-related knowledge. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Determine acceptability of the Me First tool to participants immediately post-test. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||April 2014|
|Estimated Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
No Intervention: CDC Fact Sheet
Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
Behavioral: MeFirst Tailored Intervention
Participants will be lead through an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
Me First is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the Me First tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26.
|Contact: Melissa K Zochowski, MBAfirstname.lastname@example.org|
|Contact: Vanessa Dalton, MD, MPHemail@example.com|
|United States, Michigan|
|Univeristy of Michigan||Recruiting|
|Ann Arbor, Michigan, United States, 48106|
|Principal Investigator: Vanessa K Dalton, MD, MPH|